Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wilson Jennifer G, Grandits Greg A, Grund Birgit, Mistry Shweta S, Leroux Carolyn, Ringor Angelika, Aggarwal Neil R, Murray Daniel D, Barkauskas Christina E, Brown Samuel M, Higgs Elizabeth, Shaw-Saliba Kathryn, Rupert Adam, Kan Virginia L, Beitler Jeremy R, Awan Omar, Sturgill Jamie L, Dawood Halima, Kalil Andre C, Kalomenidis Ioannis, Duggal Abhijit, Sasson Sarah C, Ho Minh Q, Nguyen Hien H, Lundgren Jens D, Ginde Adit A, Self Wesley H, Lane H Clifford, Matthay Michael A, Rogers Angela J, Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE) Network and Therapeutics for Inpatients with COVID-19 (TICO) Trial Study Group
Аннотация
DESIGN: This was a nested case-control study of COVID-19 patients enrolled in the Accelerating COVID-19 Therapeutic Interventions and Vaccines-3 (ACTIV-3)/Therapeutics for Inpatients with COVID-19 (TICO) platform trial who were on less than 20 L/min supplemental oxygen at enrollment. We compared baseline measurements of lung injury biomarkers between participants who progressed to respiratory failure or died by study day 10 (cases) and matched controls who did not progress to respiratory failure or death. Cases and controls were matched 1:1 on age, baseline oxygen requirement, immunomodulator use, and study arm.
SETTING: Hospitals enrolling in the ACTIV-3/TICO trials.
PATIENTS: Four hundred five cases and 405 matched controls.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Baseline levels of plasma interleukin (IL)-6, IL-8, IL-18, tumor necrosis factor receptor, angiopoietin-2, soluble receptor for advanced glycation end-products (sRAGE), C-reactive protein (CRP), and surfactant protein D (SPD) were compared between cases and controls using matched logistic regression. Forward variable selection was used to identify biomarkers that were independently associated with progression to respiratory failure or death in a multivariate model. All lung injury biomarkers with the exception of SPD were significantly associated with progression to respiratory failure or death, with sRAGE demonstrating the highest odds ratio (OR) for each doubling of biomarker level (OR, 1.85; 95% CI, 1.61-2.12). In multivariate regression analysis, sRAGE, IL-6, and CRP were independently associated with progression, with sRAGE as the biomarker with the strongest association.
CONCLUSIONS: Baseline levels of plasma lung injury biomarkers are significantly associated with progression to respiratory failure or death among hospitalized COVID-19 patients without respiratory failure at admission. These findings support the potential utility of measuring lung injury biomarkers in patients hospitalized without respiratory failure and should be tested in more heterogeneous patient groups including non-COVID-19 cohorts.